GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acer Therapeutics Inc (OTCPK:ACER) » Definitions » PS Ratio

Acer Therapeutics (Acer Therapeutics) PS Ratio : (As of Apr. 27, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Acer Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Acer Therapeutics's share price is $0.6601. Acer Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00. Hence, Acer Therapeutics's PS Ratio for today is .

The historical rank and industry rank for Acer Therapeutics's PS Ratio or its related term are showing as below:

During the past 13 years, Acer Therapeutics's highest PS Ratio was 148.80. The lowest was 1.24. And the median was 17.23.

ACER's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.92
* Ranked among companies with meaningful PS Ratio only.

Acer Therapeutics's Revenue per Sharefor the three months ended in Jun. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00.

During the past 12 months, the average Revenue per Share Growth Rate of Acer Therapeutics was -100.00% per year.

During the past 13 years, Acer Therapeutics's highest 3-Year average Revenue per Share Growth Rate was -15.10% per year. The lowest was -15.10% per year. And the median was -15.10% per year.

Back to Basics: PS Ratio


Acer Therapeutics PS Ratio Historical Data

The historical data trend for Acer Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acer Therapeutics PS Ratio Chart

Acer Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 25.91 -

Acer Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.40 55.60 - - -

Competitive Comparison of Acer Therapeutics's PS Ratio

For the Biotechnology subindustry, Acer Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acer Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acer Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Acer Therapeutics's PS Ratio falls into.



Acer Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Acer Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.6601/0
=

Acer Therapeutics's Share Price of today is $0.6601.
Acer Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Acer Therapeutics  (OTCPK:ACER) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Acer Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Acer Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Acer Therapeutics (Acer Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
300 Washington Street, One Gateway Center, Suite 351, Newton, MA, USA, 02458
Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.
Executives
Chris Schelling director, officer: President and Chief Executive C/O ACER THERAPEUTICS INC., 222 THIRD STREET, CAMBRIDGE MA 02142
Steve Aselage director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Tanya Hayden officer: Chief Operating Officer 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Adrian W Quartel officer: Chief Medical Officer 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Bernard H Paul officer: Chief People Officer 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Jefferson E Davis officer: Chief Business Officer 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
John Michael Dunn director C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Donald Joseph officer: Chief Legal Officer and Secy C/O KALOBIOS PHARMACEUTICALS, INC., 260 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John Michael Klopp officer: Chief Technology Officer ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458
Matthew Seibt officer: Chief Commercial Officer ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Harry S Palmin officer: Chief Opp. and Financial Offr C/O NOVELOS THERAPUETICS, INC., ONE GATEWAY CENTER,SUITE 504, NEWTON MA 02458
William T. Andrews officer: Chief Medical Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Jason Amello director 500 KENDALL STREET, CAMBRIDGE MA 01824
Salma Jutt-eghbali officer: Chief Commercial Officer ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458

Acer Therapeutics (Acer Therapeutics) Headlines

From GuruFocus

Acer Therapeutics Announces $1.5M Private Placement

By Value_Insider Value_Insider 11-30-2022

Is Acer Therapeutics Inc Undervalued Following the Latest Insider Buy?

By GuruFocus Research GuruFocus Editor 12-02-2022